Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of fibrate treatment in dyslipidemia: an overview.

Current pharmaceutical design·2013
Same author

Ezetimibe therapy for dyslipidemia: an update.

Current pharmaceutical design·2013
Same author

Colesevelam: a new and improved bile acid sequestrant?

Current pharmaceutical design·2013
Same author

Hydrochlorothiazide vs. chlorthalidone as the optimal diuretic for the management of hypertension.

Current pharmaceutical design·2013
Same author

PCSK9 inhibition - a novel mechanism to treat lipid disorders?

Current pharmaceutical design·2013
Same author

Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?

Current pharmaceutical design·2013

Related Experiment Video

Updated: Jul 4, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statins and heart failure.

Theodosios D Filippatos1, Dimitri P Mikhailidis

  • 1Department of Clinical Biochemistry, Vascular Disease Prevention Clinics, Royal Free Hospital Campus, University College London (UCL), London, United Kingdom.

Angiology
|May 30, 2008
PubMed
Summary
This summary is machine-generated.

Statins may prevent heart failure and reduce mortality. However, a trial found rosuvastatin did not significantly improve outcomes in advanced heart failure patients, suggesting early statin use is crucial for coronary heart disease patients.

Related Experiment Videos

Last Updated: Jul 4, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Retrospective studies suggest statins prevent congestive heart failure (CHF) and decrease mortality.
  • Limited prospective data exists on statin efficacy in advanced CHF.

Purpose of the Study:

  • To evaluate the efficacy of rosuvastatin in patients with advanced coronary heart disease-related CHF.

Main Methods:

  • The Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) study.
  • Compared rosuvastatin (10 mg/d) with placebo in patients with advanced CHF.

Main Results:

  • No significant difference in mortality or major adverse cardiac events between rosuvastatin and placebo.
  • Rosuvastatin group showed a trend towards reduced hospitalization rates.

Conclusions:

  • Rosuvastatin did not demonstrate significant benefits in patients with advanced CHF.
  • Early initiation of statin therapy in coronary heart disease patients is recommended.